Mendus AB (“Mendus” publ; IMMU.ST), will publish its interim report for the first quarter 2026 on Friday May 8 at 08.00 CEST. The company will host a live presentation and business update on the same day at 14.00 CEST. The presentation will be held in English and includes a Q&A session.
Date and time: May 8 at 14.00 CEST
If you wish to participate via webcast please use the link below. Via the audiocast you are able to ask written questions.
https://mendus.events.inderes.com/q1-report-2026/register
If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/mendus/q1-report-2026/dial-in
For more information, please contact:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies that combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/
Attachments
Invitation to presentation of Mendus' first quarter 2026 financial report
© Modular Finance, source Nordic Press Releases